Interim report January – June 2023 for CombiGene AB (publ)

Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här

Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Interim report January – June 2023 for CombiGene AB (publ)

MARKN.

April – June 2023
• Net sales: TSEK 1,788 (4,738).
• Other operating revenues: TSEK 1,413 (9,800).
• Profit from financial items: TSEK -6,286 (4,516).
• Earnings per share: SEK -0.32 (0.23).

January – June 2023
• Net sales: TSEK 3,955 (16,141).
• Other operating revenues: TSEK 543 (12,602).
• Profit from financial items: TSEK -20,903 (1,832).
• Earnings per share: SEK -1.06 (0.09).
• Cash and cash equivalents: TSEK 115,442 (125,953).

Events during the period
• Gene Therapy, one of Nature’s journals, publishes an article about CombiGene’s epilepsy project authored by Esbjörn Melin, scientist at CombiGene.
• High activity level in the pain program COZY in preparation of the final preclinical toxicology program in the peptide project COZY01.
• CombiGene to play an integral part in the development of a national infrastructure for ATMPs. CombiGene’s CEO Jan Nilsson elected Chairman of the Board of CCRM Nordic AB.
• CombiGene forms prominent Scientific Advisory Board within the pain program COZY.
• Jan Nilsson leaves his position as CEO of CombiGene – COO Peter Ekolind takes over as new CEO on September 1, 2023.

Events after the end of the period
• There have been no significant events after the end of the period.

About CombiGene

CombiGene’s vision is to offer patients affected by severe life‐changing diseases opportunities for a better life through innovative gene therapies. CombiGene’s business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to preclinical/clinical concept verification. Drug candidates for common diseases will be co‐developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in‐house for medicines aimed at limited patient populations.

The company has an exclusive collaboration and license agreement with Spark Therapeutics for the CG01 project and a collaboration agreement with the Danish company Zyneyro within the pain program COZY.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, info@fnca.se.

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282.
CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714

Datum	2023-08-25, kl 09:00
Källa	MFN

Bifogade filer

CombiGene Q2 2023 EN

LOGGA IN

Lärkberget

Affiliate

Interim report January – June 2023 for CombiGene AB (publ)